Rury Holman founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 325 peer-reviewed papers that have been cited more than 55,000 times.

In this seminar he will discuss results from the recently completed EXSCEL and ACE trials. EXSCEL tested the addition of once weekly exenatide (GLP-1 receptor agonist) therapy to standard diabetes treatment in high risk diabetic individuals, while the ACE trial investigated whether lowering post-prandial glucose in people at high risk of diabetes was beneficial.